# A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

> **NCT03594123** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 259 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Brexpiprazole
- **DRUG:** Brexpiprazole

## Key facts

- **NCT ID:** NCT03594123
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-11
- **Primary completion:** 2022-09-19
- **Final completion:** 2022-09-19
- **Target enrollment:** 259 (ACTUAL)
- **Last updated:** 2023-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03594123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03594123, "A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03594123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*